You are here: Industry Insights > Yervoy

News List

Opdivo/Yervoy improves survival in pleural mesothelioma pharmatimes
August 11, 2020
Bristol-Myers Squibb’s immunotherapy combination treatment Opdivo (nivolumab) plus Yervoy (ipilimumab) improved survival in patients with previously untreated, malignant pleural mesothelioma (MPM).
FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastati pharmaceutical-business-review
May 29, 2020
Bristol Myers Squibb announced that Opdivo (nivolumab) 360 mg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) given with two cycles of platinum-doublet chemotherapy was approved by the U.S. Food and Drug Administration (FDA) ...
U.S. Food and Drug Administration approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for patients with hepatocellular carcinoma (HCC) previously treated with sorafenib worldpharmanews
March 12, 2020
Bristol Myers Squibb Company announced that Opdivo (nivolumab) 1 mg/kg plus Yervoy (ipilimumab) 3 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) to treat hepatocellular carcinoma (HCC) in patients ...
Opdivo/Yervoy continues to impress in kidney cancer pharmatimes
March 10, 2020
Bristol-Myers Squibb has announced that its Opdivo (nivolumab) and Yervoy (ipilimumab) combo has demonstrated superior overall survival, complete response rates and objective response rates at 42 months ...
BMS secures FDA priority review for NSCLC treatment combination pharmaceutical-technology
January 17, 2020
Bristol-Myers Squibb Company (BMS) has secured the US Food and Drug Administration (FDA) priority review for a drug combination to treat metastatic or recurrent non-small cell lung cancer (NSCLC).
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination for Patients with Previously Treated Advanced Hepatocellular Carcinoma En-CPhI.CN
November 13, 2019
The FDA also granted Opdivo plus Yervoy Breakthrough Therapy Designation for this potential indication.
Opdivo, Yervoy Combination Study Meets Co-Primary Endpoint americanpharmaceuticalreview
July 26, 2019
Bristol-Myers Squibb announced Part 1a of the Phase 3 CheckMate -227 trial evaluating Opdivo® (nivolumab) plus low-dose Yervoy® (ipilimumab) met the co-primary endpoint of overall survival (OS) ...
Opdivo Plus Yervoy Shows Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer americanpharmaceuticalreview
February 18, 2019
Bristol-Myers Squibb Company announced data evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in patients with metastatic castration-resistant prostate cancer (mCRPC)....
BMS gets new OK for Opdivo/Yervoy in kidney cancer pharmaphorum
January 17, 2019
Bristol-Myers Squibb has claimed a new approval for its immuno-oncology combination of Opdivo and Yervoy, getting a green light from the European Medicines Agency (EMA) for its use in renal cell carcinoma (RCC), the most common form of kidney cancer.
NICE turns down Opdivo/Yervoy combo for kidney cancer pharmatimes
December 11, 2018
The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funds for Opdivo/Yervoy for untreated metastatic renal cell carcinoma.

Previous page 1 2 3 Next page